These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8917325)

  • 1. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
    Rackley CE
    Postgrad Med; 1996 Nov; 100(5):61-5, 70-2. PubMed ID: 8917325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P
    Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
    Jacobson TA
    Am J Cardiol; 1996 Sep; 78(6A):32-41. PubMed ID: 8875973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
    Weber C; Erl W; Weber KS; Weber PC
    J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
    Fujita R; Matsushima T
    Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
    Miyake Y; Shouzu A; Nishikawa M; Yonemoto T; Shimizu H; Omoto S; Hayakawa T; Inada M
    Arzneimittelforschung; 1999 Apr; 49(4):324-9. PubMed ID: 10337451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
    Davidson MH
    Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
    Rackley CE
    Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative tolerability of the HMG-CoA reductase inhibitors.
    Farmer JA; Torre-Amione G
    Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological effects of HMG-CoA reductase inhibitors].
    Tomita N; Morishita R; Ogihara T
    Nihon Rinsho; 2002 May; 60(5):955-61. PubMed ID: 12029999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of recent large cholesterol-lowering trials and implications for clinical management.
    Gotto AM
    Am J Cardiol; 1997 Jun; 79(12):1663-6. PubMed ID: 9202359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.
    Naslafkih A; Sestier F
    J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and clinical experience with simvastatin.
    Hess DC; Fagan SC
    Expert Opin Pharmacother; 2001 Jan; 2(1):153-63. PubMed ID: 11336576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.